By Fineline Cube China-based Chia Tai Tianqing has announced the first batch prescriptions in China for its efbemalenograstim alfa (F-627), an in-house developed long-acting recombinant human granulocyte colony stimulating factor (rhGCSF)-Fc fusion protein. The drug is indicated for the prevention and treatment of neutropenia during chemotherapy in cancer patients. F-627 received marketing approval earlier last month, marking a significant milestone in the company’s pharmaceutical portfolio.
F-627: A First-in-Class rhG-CSF with Di-Kine Bimolecular Technology
F-627 is characterized as a first-in-class rhG-CSF developed using the Di-Kine bimolecular technology platform, which confers long-lasting and potent biological characteristics. This innovative approach to rhG-CSF development positions F-627 as a potentially superior option for managing neutropenia, a common side effect of chemotherapy.
First Prescription and Hospital Implementation
The first prescription of F-627 was administered on June 22, 2023, at the Nanjing Jiangning Hospital. This event signifies the commencement of F-627’s clinical use in China, providing a new therapeutic option for cancer patients undergoing chemotherapy and at risk of neutropenia.-Fineline Info & Tech